Shares of vaccine maker Moderna fell Wednesday as Goldman Sachs lowered its rating after the biotech’s second cut to product ...
Despite continued underperformance in 2024, the biotech sector enters 2025 with a brighter outlook driven by groundbreaking ...
"This type of gene editing should also allow for the treatment of diseases whose origin is not genetic or whose origin cannot ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback